Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added related topics 'Multiple myeloma' and 'MedlinePlus Genetics', and updated the page revision to v3.3.3. Removed the 'HHS Vulnerability Disclosure' link and the previous revision v3.3.2.
    Difference
    0.3%
    Check dated 2025-12-22T01:50:21.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.2, replacing the previous Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-30T16:14:11.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Publications section now includes a note that items are automatically filled from PubMed, and a Revision: v3.3.1 was added. The earlier language about PubMed publications and related topics (including MedlinePlus Genetics) and the Revision: v3.2.0 entry were removed; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-23T14:53:39.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    A government funding/operating status notice was removed from the page, which does not affect the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-16T14:32:10.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Added related topics: Multiple myeloma and MedlinePlus Genetics in the page's resources/related topics area, providing quick access to background information. The update does not modify the trial data or eligibility criteria.
    Difference
    0.2%
    Check dated 2025-11-09T04:59:20.000Z thumbnail image
  8. Check
    55 days ago
    Change Detected
    Summary
    From the two screenshots, core study information (title, NCT number, study design, enrollment, and eligibility criteria) appears unchanged; only visual layout and formatting adjustments are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-02T00:51:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.